A real-world, multicenter, observational study of efficacy and safety of amlodipine/losartan-based SPCs [amlodipine + losartan (AL), amlodipine + losartan + rosuvastatin (ALR), and amlodipine + losartan + chlorthalidone (ALC)] therapies in patients with hypertension
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Amlodipine/chlortalidone/losartan (Primary) ; Amlodipine/losartan (Primary) ; Amlodipine/losartan/rosuvastatin (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2021 New trial record
- 29 Oct 2021 Results published in the Journal of Clinical Hypertension (Greenwich)